SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

IMMUNOGENICITY AND IMPACT ON NASOPHARYNGEAL CARRIAGE OF A SINGLE DOSE OF PCV10 GIVEN TO VIETNAMESE CHILDREN AT 18 MONTHS OF AGE.

Higgins, RA; Temple, B; Dai, VTT; Phan, TV; Toan, NT; Spry, L; Toh, ZQ; Nation, ML; Ortika, BD; Uyen, DY; et al. Higgins, RA; Temple, B; Dai, VTT; Phan, TV; Toan, NT; Spry, L; Toh, ZQ; Nation, ML; Ortika, BD; Uyen, DY; Cheung, YB; Nguyen, CD; Bright, K; Hinds, J; Balloch, A; Smith-Vaughan, H; Huu, TN; Mulholland, K; Satzke, C; Licciardi, PV (2021) IMMUNOGENICITY AND IMPACT ON NASOPHARYNGEAL CARRIAGE OF A SINGLE DOSE OF PCV10 GIVEN TO VIETNAMESE CHILDREN AT 18 MONTHS OF AGE. Lancet Reg Health West Pac, 16. p. 100273. ISSN 2666-6065 https://doi.org/10.1016/j.lanwpc.2021.100273
SGUL Authors: Hinds, Jason

[img]
Preview
PDF Published Version
Available under License Creative Commons Attribution.

Download (1MB) | Preview

Abstract

Background: This study investigated the immunogenicity and impact on nasopharyngeal carriage of a single dose of PCV10 given to 18-month-old Vietnamese children. This information is important for countries considering catch-up vaccination during PCV introduction and in the context of vaccination during humanitarian crises. Methods: Two groups of PCV-naïve children within the Vietnam Pneumococcal Project received PCV10 (n=197) or no PCV (unvaccinated; n=199) at 18 months of age. Blood samples were collected at 18, 19, and 24 months of age, and nasopharyngeal swabs at 18 and 24 months of age. Immunogenicity was assessed by measuring serotype-specific IgG, opsonophagocytosis (OPA) and memory B cells (Bmem). Pneumococci were detected and quantified using real-time PCR and serotyped by microarray. Findings: At 19 months of age, IgG and OPA responses were higher in the PCV10 group compared with the unvaccinated group for all PCV10 serotypes and cross-reactive serotypes 6A and 19A. This was sustained out to 24 months of age, at which point PCV10-type carriage was 60% lower in the PCV10 group than the unvaccinated group. Bmem levels increased between 18 and 24 months of age in the vaccinated group. Interpretation: We demonstrate strong protective immune responses in vaccinees following a single dose of PCV10 at 18 months of age, and a potential impact on herd protection through a substantial reduction in vaccine-type carriage. A single dose of PCV10 in the second year of life could be considered as part of catch-up campaigns or in humanitarian crises to protect children at high-risk of pneumococcal disease.

Item Type: Article
Additional Information: © 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)
SGUL Research Institute / Research Centre: Academic Structure > Infection and Immunity Research Institute (INII)
Journal or Publication Title: Lancet Reg Health West Pac
ISSN: 2666-6065
Language: eng
Dates:
DateEvent
November 2021Published
20 September 2021Published Online
24 August 2021Accepted
Publisher License: Creative Commons: Attribution 4.0
Projects:
Project IDFunderFunder ID
566792National Health and Medical Research Councilhttp://dx.doi.org/10.13039/501100000925
OPP1116833Bill and Melinda Gates Foundationhttp://dx.doi.org/10.13039/100000865
1146198National Health and Medical Research Councilhttp://dx.doi.org/10.13039/501100000925
1087957National Health and Medical Research Councilhttp://dx.doi.org/10.13039/501100000925
PubMed ID: 34590071
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/113737
Publisher's version: https://doi.org/10.1016/j.lanwpc.2021.100273

Actions (login required)

Edit Item Edit Item